Introduction Faecal calprotectin is extremely sensitive to gut inflammation, and as such, is less sensitive to the diagnosis of inflammatory bowel disease (IBD) in patients presenting with acute symptoms. Local guidelines suggest faecal calprotectin test to be performed in patients between the ages of 18 and 50, with lower gastrointestinal symptoms with loose stools for longer than four weeks. Methods All inpatient faecal calprotectin requests in 2019 at the Royal Glamorgan Hospital (RGH) were obtained. Data collection included patient identifiable number, request indication, faecal calprotectin level, current IBD status, presenting symptom, if endoscopy was conducted and if a new diagnosis of IBD was made. Results There were 63 inpatients who had faecal calprotectin tests performed, of which 44 were adult patients (>18-year-old). Only adult patients were included in this study. The patients were categorized into faecal calprotectin level groups. Four patients(9%) were known to have IBD, all of whom have levels >600. The most common request indication was diarrhoea (18 patients; 40%), of which twelve had ‘ongoing diarrhoea’. Nineteen patients (50%) had some form of endoscopy performed. Table 1 shows the percentage of patients who had endoscopy in the respective faecal calprotectin level groups. A new diagnosis of IBD was made on three patients, all of whom had faecal calprotectin levels >600. Indications for the initial faecal calprotectin tests include ‘ongoing diarrhoea’, rectal bleeding and ‘colitis on imaging’.